Literature DB >> 9222352

Mutation of a major histocompatibility class I locus, H-2D, leads to an increased virus burden and disease susceptibility in Theiler's virus-induced demyelinating disease.

H L Lipton1, R Melvold, S D Miller, M C Dal Canto.   

Abstract

Genetic studies have demonstrated that susceptibility to Theiler's murine encephalomyelitis virus (TMEV)-induced demyelinating disease is multigenic with linkage to the MHC class I locus, H-2D. We have analyzed the effect of mutations (H-2bm13 and H-2bm14) in the H-2Db gene on central nervous system (CNS) virus replication, virus-specific delayed type hypersensitivity (DTH) and disease induction in mutant [bm14D2F1 and bm13D2F1] and parental B6D2F1 hybrids. The results indicate that substitutions of only a single residue (bm14D2F1) or three residues (bm13D2F1) in H-2D in the mutant leads to a sequence of events culminating in disease susceptibility. Mutation of the H-2D gene is associated with reduced or delayed virus clearance following the acute phase of exponential CNS virus growth and an increased level of virus persistence. Concomittant with the greater virus antigen burden, mutant mice respond with higher levels of virus-specific DTH and develop inflammatory demyelinating lesions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9222352     DOI: 10.3109/13550289509113960

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  14 in total

1.  Two loci, Tmevp2 and Tmevp3, located on the telomeric region of chromosome 10, control the persistence of Theiler's virus in the central nervous system of mice.

Authors:  F Bihl; M Brahic; J F Bureau
Journal:  Genetics       Date:  1999-05       Impact factor: 4.562

2.  Viral load increases in SJL/J mice persistently infected by Theiler's virus after inactivation of the beta(2)m gene.

Authors:  S Aubagnac; M Brahic; J F Bureau
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Bone marrow chimeras reveal non-H-2 hematopoietic control of susceptibility to Theiler's virus persistent infection.

Authors:  Stéphanie Aubagnac; Michel Brahic; Jean-François Bureau
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Virus expanded regulatory T cells control disease severity in the Theiler's virus mouse model of MS.

Authors:  Maureen H Richards; Meghann Teague Getts; Joseph R Podojil; Young-Hee Jin; Byung S Kim; Stephen D Miller
Journal:  J Autoimmun       Date:  2011-01-26       Impact factor: 7.094

5.  Preferential induction of protective T cell responses to Theiler's virus in resistant (C57BL/6 x SJL)F1 mice.

Authors:  Young-Hee Jin; Hyun Seok Kang; Mani Mohindru; Byung S Kim
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

6.  H-2D(b-/-) mice are susceptible to persistent infection by Theiler's virus.

Authors:  A Azoulay-Cayla; S Dethlefs; B Pérarnau; E L Larsson-Sciard; F A Lemonnier; M Brahic; J F Bureau
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

7.  Chromosome 14 contains determinants that regulate susceptibility to Theiler's virus-induced demyelination in the mouse.

Authors:  J F Bureau; K M Drescher; L R Pease; T Vikoren; M Delcroix; L Zoecklein; M Brahic; M Rodriguez
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

Review 8.  Targeting the B7 family of co-stimulatory molecules: successes and challenges.

Authors:  Joseph R Podojil; Stephen D Miller
Journal:  BioDrugs       Date:  2013-02       Impact factor: 5.807

9.  Pro-inflammatory functions of astrocytes correlate with viral clearance and strain-dependent protection from TMEV-induced demyelinating disease.

Authors:  Pamela A Carpentier; Meghann Teague Getts; Stephen D Miller
Journal:  Virology       Date:  2008-03-04       Impact factor: 3.616

10.  Critical role for protein tyrosine phosphatase SHP-1 in controlling infection of central nervous system glia and demyelination by Theiler's murine encephalomyelitis virus.

Authors:  Paul T Massa; Stacie L Ropka; Sucharita Saha; Karen L Fecenko; Kathryn L Beuler
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.